Repros Therapeutics is a development-stage biopharmaceutical company focused on the development of oral small molecule drugs to address major unmet medical needs for male and female reproductive disorders. The company’s primary product candidate is Androxal, an orally active proprietary small molecule compound being developed for men of reproductive age with low testosterone levels. Androxal is additionally being studied for treating hypogonadal men with type 2 diabetes. For more information, visit the company’s Web site at www.reprosrx.com

ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year’s annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 11-14. Bringing together executives from more than 400 growth companies, the 24th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com

Let us hear your thoughts below: